News Release Details
Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock
Nov 26, 2018
|
All the shares in the offering are to be sold by Rocket. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.
Rocket intends to use the net proceeds from the offering to fund the continued development of its pipeline of gene therapies for rare diseases, enhancements to in-house manufacturing, and general corporate purposes.
BofA Merrill Lynch, Cowen and Evercore ISI are acting as joint
book-running managers for the public offering.
The public offering is being made by Rocket pursuant to an effective
shelf registration statement on Form S-3 that was previously filed with
the
This press release does not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Forward-looking Statements
Various statements in this release concerning Rocket’s future
expectations, plans and prospects, including without limitation,
Rocket’s expectations regarding the consummation of the offering, the
terms of the offering, and the satisfaction of customary closing
conditions with respect to the offering and the anticipated use of the
net proceeds of the offering, may constitute forward-looking statements
for the purposes of the safe harbor provisions under The Private
Securities Litigation Reform Act of 1995 and other federal securities
laws and are subject to substantial risks, uncertainties and
assumptions. You should not place reliance on these forward-looking
statements, which often include words such as “anticipate,” “believe,”
“contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,”
“may,” “plan,” “potential,” “predict,” “project,” “seek,” “should,”
“suggest,” “target,” “will,” “will give,” “would,” or similar terms,
variations of such terms or the negative of those terms. Although Rocket
believes that the expectations reflected in the forward-looking
statements are reasonable, Rocket cannot guarantee such outcomes. Actual
results may differ materially from those indicated by these
forward-looking statements as a result of various important factors,
including, without limitation, changes as a result of market conditions
or for other reasons, the risk that the offering will not be
consummated, and the impact of general economic, industrial or political
conditions in
View source version on businesswire.com: https://www.businesswire.com/news/home/20181126005747/en/
Source:
Claudine Prowse, Ph.D.
SVP Corporate Development and IRO
Rocket
Pharmaceuticals, Inc.
The Empire State Building, Suite 7530
New
York, NY 10118
www.rocketpharma.com
investors@rocketpharma.com